NCT04956601Not yet recruiting
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification
Source: ClinicalTrials.gov · Last updated 9 Jul 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- First submitted
- 2 Jul 2021
- Start date
- 1 Jul 2021
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Endometrial cancer
- NCT number
- NCT04956601
What you commit to
- Study type: Interventional
- Planned participants: 480
- From 1 Jul 2021 to the primary completion date, 31 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patients receive chemotherapy;
- Previous diagnosis of Crohn's disease or ulcerative colitis.
Other illness
- History of previous malignant disease;
Who the study is looking for
- Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;
- Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;
- Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;
- ECOG score is 0-2;
- The interval time between surgery and radiotherapy is no more than 8 weeks;
- The routine blood examination was normal;
- Compliance is good and informed consent is voluntarily signed.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University 3rd Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.